Parabilis Medicines's long-term debt is $34M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), PBLS shows a long-term debt of $34M. Scroll down for historical charts and peer comparison views.
Tracking PBLS's long-term debt over time shows whether Parabilis Medicines is scaling, shrinking, or reshaping that part of the business. The current reading is $34M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Parabilis Medicines's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $34M) with ownership activity and broader fundamentals.
Parabilis Medicines's long-term debt is $34M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.